MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2019 International Congress

    BouNDless: An active-controlled randomized, double-blind double-dummy study of continuous ND0612 infusion in patients with fluctuating Parkinson’s disease

    W. Poewe, K. Kieburtz, F. Stocchi, S. Oren, T. Yardeni, L. Adar, O. Rosenfeld, C. Olanow (Innsbruck, Austria)

    Objective: Determine the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral Carbidopa/Levodopa (CD/LD) in patients with Parkinson’s disease (PD) experiencing…
  • 2019 International Congress

    Influence of motor fluctuations duration, levodopa dose and duration of use in efficacy responses of Parkinson’s disease patients: post-hoc analysis from combined BIPARK-I and II.

    A. Santos, A. Lees, J. Ferreira, O. Rascol, A. Antonini, F. Ikedo, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

    Objective: To evaluate the impact of motor fluctuations (MF) duration, levodopa dose and levodopa duration of use (LDU) in efficacy responses of levodopa-treated Parkinson’s Disease…
  • 2019 International Congress

    A randomized, placebo-controlled, double-blind clinical study in Japan of Opicapone treatment for Parkinson’s Disease -Comfort-PD Study part 1

    A. Takeda, R. Takahashi, Y. Tsuboi, M. Nomoto, T. Maeda, A. Nishimura, N. Hattori (Sendai, Japan)

    Objective: To investigate efficacy and safety of two doses of Opicapone (OPC) compared to placebo administered once daily for 14 to 15 weeks to Japanese…
  • 2019 International Congress

    Using cognitive computing to identify existing drugs with potential to stabilize mitophagy pathways associated with Parkinson’s Disease

    N. Visanji, N. Moskal, G. Shi, A. Lacoste, S. Spangler, P. Lewis, A. Mcquibban (Toronto, ON, Canada)

    Objective: We applied IBM Watson for Drug Discovery (WDD), a cognitive computing platform that uses natural language processing, to identify compounds with the potential to…
  • 2019 International Congress

    Polysomnographic features of Spinocerebellar Ataxia type 3 – a case report

    DRC. Carneiro, IL. Luzeiro, ASM. Morgadinho (Coimbra, Portugal)

    Objective: To describe, through a case report, the range of abnormal sleep patterns of Spinocerebellar Ataxia type 3 (SCA3). Background: SCA3 is a progressive neurodegenerative…
  • 2019 International Congress

    Lower urinary tract symptoms and urodynamic findings in SCAs

    M. Jang, H. Kim, B. Jeon, A. Kim (Jeonju, Republic of Korea)

    Objective: Characterization of urinary dysfunctions in SCAs is needed not only for the understanding of SCAs but also for the correct diagnosis in patients with…
  • 2019 International Congress

    Gait in Spinocerebellar Ataxia Type12 (SCA-12)

    M. Narang, A. Srivastava, R. Aggarwal, R. Rajan, M. Faruq, M. Srivastava (Delhi, India)

    Objective: The aim of our study was to evaluate the spatial and temporal parameters of gait in SCA12 patients and to compare it with healthy…
  • 2019 International Congress

    The severity of motor dysfunctions and autonomic dysfunctions are not correlated in multiple system atrophy

    T. Yamamoto, Y. Yamanaka, A. Sugiyama, S. Hirano, T. Uchiyama, M. Asahina, R. Sakakibara, S. Kuwabara (Chiba, Japan)

    Objective: Although it is well known that patients with multiple system atrophy (MSA) cerebellar dominant type (MSA-C) show severe autonomic dysfunction, the relationship between autonomic…
  • 2019 International Congress

    Steroid responsive chorea in Moyamoya disease: illustrative cases

    S. Medarametla, N. Boraiah, S. Swamy, S. Raju (Bangalore, India)

    Objective: To report the rapid reduction of disabling chorea in two cases of pediatric Moyamoya disease with pulse steroid therapy. Background: The common clinical presentation…
  • 2019 International Congress

    Dancing larynx syndrome associated with trigeminal neuralgia secondary to multiple sclerosis

    D. Shpiner, M. Ortega, H. Moore (Miami, FL, USA)

    Objective: To describe a rare a case of a patient who developed “dancing larynx”-like syndrome after gamma knife radiation for trigeminal neuralgia (TN) associated with…
  • « Previous Page
  • 1
  • …
  • 111
  • 112
  • 113
  • 114
  • 115
  • …
  • 217
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley